XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2
The Company (Details)
6 Months Ended
Jun. 30, 2022
USD ($)
Segment
product
Jan. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Sep. 30, 2019
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]          
Number of operating segments | Segment 1        
Number of FDA approved products | product 2        
Deferred revenue, non-current $ 70,438,000   $ 64,315,000    
Total cash, cash equivalents and investments, Fair Value 184,372,000   139,801,000    
Second Santen Agreement | License Revenue, Upfront Payment          
Organization, Consolidation and Presentation of Financial Statements [Line Items]          
Deferred revenue, non-current   $ 90,000,000 88,000,000 $ 50,000,000  
Second Santen Agreement | License Revenue, Additional Upfront Paymet          
Organization, Consolidation and Presentation of Financial Statements [Line Items]          
Deferred revenue, non-current     2,000,000    
Convertible Senior Notes          
Organization, Consolidation and Presentation of Financial Statements [Line Items]          
Principal amount         $ 316,250,000
Interest rate         1.50%
Convertible Senior Notes Due 2024 | Convertible Senior Notes          
Organization, Consolidation and Presentation of Financial Statements [Line Items]          
Principal amount $ 316,250,000   $ 316,250,000   $ 316,250,000
Interest rate         1.50%